Different sensitivities of rat skeletal muscles and brain to novel anti‐cholinesterase agents, alkylammonium derivatives of 6‐methyluracil (ADEMS)

Abstract

The rat respiratory muscle diaphragm has markedly lower sensitivity than the locomotor muscle extensor digitorum longus (EDL) to the new acetylcholinesterase (AChE) inhibitors, alkylammonium derivatives of 6-methyluracil (ADEMS). This study evaluated several possible reasons for differing sensitivity between the diaphragm and limb muscles and between the muscles and the brain. EXPERIMENTAL APPROACHIncreased amplitude and prolonged decay time of miniature endplate currents were used to assess anti-cholinesterase activity in muscles. In hippocampal slices, induction of synchronous network activity was used to follow cholinesterase inhibition. The inhibitor sensitivities of purified AChE from the EDL and brain were also estimated. KEY RESULTSThe intermuscular difference in sensitivity to ADEMS is partly explained caused by a higher level of mRNA and activity of 1,3-bis[5(diethyl-o-nitrobenzylammonium)pentyl]-6-methyluracildibromide (C-547)-resistant BuChE in the diaphragm. Moreover, diaphragm AChE was more than 20 times less sensitive to C-547 than that from the EDL. Sensitivity of the EDL to C-547 dramatically decreased after treadmill exercises that increased the amount of PRiMA AChE(G4), but not ColQ AChE(A12) molecular forms. The A12 form present in muscles appeared more sensitive to C-547. The main form of AChE in brain, PRiMA AChE(G4), was apparently less sensitive because brain cholinesterase activity was almost three orders of magnitude more resistant to C-547 than that of the EDL. CONCLUSIONS AND IMPLICATIONSOur findings suggest that ADEMS compounds could be used for the selective inhibition of AChEs and as potential therapeutic tools. AbbreviationsAChE, acetylcholinesterase; ADEMS, alkylammonium derivatives of 6

Regulation of acetylcholinesterase activity by nitric oxide in rat neuromuscular junction via N‐methyl‐d‐aspartate receptor activation

“…The recorded responses were filtered (bandpass 0.03–10 kHz) and digitized at 10–20 μs intervals. The mEPCs were analysed using an original computer program designed to determine the amplitude and e‐fold decay time constant (Petrov et al ., ). The decay time constant (τ) was estimated as the time interval between 0.8 and 0.367 of the mEPC amplitude (e‐fold decrease).…”

Crystallization and preliminary X-ray study ofVibrio choleraeuridine phosphorylase in complex with 6-methyluracil

“…To confirm this hypothesis, Krajewska and Shugar initiated investigation of the spatial organization of the complex of uridine phosphorylase from the pathogenic microorganism V. cholerae of biotype eltor in serogroup O1 (VchUPh) with 6-methyluracil (6-MU). 6-MU is used to stimulate immunodefence, as an anabolic drug and as an adjuvant in antibiotic therapy (Chadaev & Klimiashvili, 2003;el-On & Weinrauch, 1990;Ganzhii, 2002;Gerasimenko et al, 2002;Petrov et al, 2011;Taran & Shishkina, 1993).…”

Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes

“…In this case, the sequences of inhibited synaptic AChE are: (i) more ACh molecules reach the postsynaptic membrane without being catalytically hydrolyzed by AChE during their diffusion across the synaptic cleft, and therefore, more AChRs are activated; (ii) because of prolonged lifespan in synaptic cleft, ACh molecules activate AChRs sustainably. Electrophysiological recordings show that prolonged lifetime of ACh in synaptic cleft due to AChE inactivation results in the increase of amplitude and duration of mEPPs ( Katz and Miledi, 1975 ; Petrov et al, 2006 , 2009 , 2011 ). This fact is in agreement with idea that the main function of AChE in synaptic cleft is to control the duration of ACh action on postsynaptic AChRs.…”